ARMP
Armata Pharmaceuticals Inc
3.90$
+1.3%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -24.1% | +31.8% | -3.4% | +35.7% | -47.4% | +0.0% | – | – | – | – | – | – | – | – | – | +829.0% | +75.0% | +111.5% | +9.6% | +7.1% | -20.9% | +25.0% | +52.3% | -28.9% | -21.4% | -24.3% | +23.1% | +25.0% | +24.7% | -36.8% | -100.0% | – | -58.5% | -60.2% | +341.8% | -46.6% | -6.4% | -27.3% | +218.1% | – | |
| – | – | – | – | – | +3.2% | +1.0% | – | – | – | – | – | – | – | – | – | +53.5% | +22.5% | -12.7% | +20.1% | +7.7% | -14.4% | +66.8% | +12.4% | -6.9% | +13.9% | +0.4% | -97.9% | +10.5% | +32.6% | +8.2% | -0.6% | -0.6% | +21.4% | -0.8% | -2.9% | +1.1% | +13.0% | +9.3% | +29.3% | – | |
| – | -24.1% | +31.8% | -3.4% | +35.7% | -47.4% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +28.7% | +23.0% | -47.4% | -148.5% | – | -67.9% | -86.7% | +1,481.6% | -56.2% | -15.5% | -50.2% | +478.0% | – | |
| – | -51.5% | +85.8% | -24.2% | -26.6% | +31.5% | +34.3% | +15.6% | -78.7% | +280.9% | +8.7% | +105.9% | -1.9% | -44.7% | +64.9% | -3.7% | +53.5% | +22.5% | -12.7% | +20.1% | +7.7% | -14.4% | +66.8% | +12.4% | -6.9% | +13.9% | +0.4% | -14.0% | -3.4% | -0.6% | +1.1% | +5.7% | +11.9% | -10.9% | -35.8% | +17.8% | -8.9% | +4.2% | +0.7% | +24.1% | – | |
| – | -13.7% | +23.5% | +46.7% | -42.1% | -19.7% | +22.9% | -14.5% | -6.2% | +15.6% | -6.4% | +50.9% | +80.5% | -45.6% | +6.2% | -9.1% | -6.5% | +7.2% | +8.8% | -0.6% | -17.3% | +25.7% | -10.8% | +5.0% | -25.1% | +16.0% | +40.2% | -7.4% | +52.5% | -11.3% | 0.0% | +8.2% | -5.7% | +2.4% | -2.1% | -19.5% | +18.8% | +10.1% | +1.1% | +51.2% | – | |
| – | -31.9% | +44.8% | +15.5% | -37.6% | -6.3% | +33.5% | -0.1% | -46.4% | +192.0% | -24.6% | +43.0% | +31.4% | -49.7% | +44.3% | -59.9% | -6.5% | +7.2% | +8.8% | -0.6% | -17.3% | +25.7% | -10.8% | +5.0% | -25.1% | +16.0% | +40.2% | +310.1% | +8.9% | -4.6% | +0.6% | +6.6% | +7.0% | -8.2% | -27.1% | +4.1% | -10.1% | +77.8% | -34.0% | +34.2% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | +219.3% | +9.3% | – | – | -24.8% | -17.4% | +7.9% | -22.4% | -10.7% | +5.6% | +18.0% | -65.0% | -96.8% | +0.0% | +3,100.0% | -98.4% | +400.0% | +80.0% | +55.6% | +22,357.1% | -100.0% | – | +23.3% | +25.5% | +49.3% | +7.5% | +12.2% | +9.8% | +5.7% | +14.1% | +11.2% | +15.0% | +19.3% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -161.0% | – | -351.2% | – | – | – | – | – | – | |
| – | – | – | – | – | -139.4% | – | -102.5% | – | – | – | +2,027.3% | -19.2% | +91.0% | -99.4% | +1,000.0% | -81.8% | +50.0% | – | – | +0.0% | -50.0% | -200.0% | – | – | – | – | -299.2% | – | – | -98.5% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -161.0% | – | -351.2% | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -118.7% | – | -140.8% | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.